Stocks Health care BCYC
NASDAQ · Health careBicycle Therapeutics PLC (BCYC)
Bicycle Therapeutics PLC brought in $83.5M of revenue over the twelve months to September 30, 2026, up 194.7% from a year earlier. It posted a net loss of $141.8M. In fiscal 2025 capital spending exceeded operating cash flow by $252M. At September 30, 2026 it held $469.9M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on October 29, 2026.
Key facts about Bicycle Therapeutics PLC
- Net worth
- Bicycle Therapeutics PLC has a market value (market cap) of $263.9M at the latest share price, and shareholders' equity of $505.3M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $72.6M (+105.8% year on year), with a net loss of $219M. Over the 12 months to September 30, 2026: revenue $83.5M, net loss $141.8M.
- Cash flow
- In fiscal 2025 operations used $249.7M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on October 29, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Bicycle Therapeutics PLC's next report is expected around March 16, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Bicycle Therapeutics PLC does
Bicycle Therapeutics PLC is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker BCYC.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $72.6M | -$219M | -$3.16 | -$252M |
| 2024 | $35.3M | -$169M | -$2.90 | -$166M |
| 2023 | $27M | -$180.7M | -$5.08 | -$63.6M |
| 2022 | $14.5M | -$112.7M | -$3.80 | -$105.1M |
| 2021 | $11.7M | -$66.8M | -$2.67 | -$16.8M |
| 2020 | $10.4M | -$51M | -$2.66 | -$19M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where BCYC ranks in Health care
Latest SEC filings
What Bicycle Therapeutics PLC has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 29, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 190% to $34.1M versus the same quarter last year; diluted EPS -$0.15 versus -$0.85.
- October 29, 2026
- August 20, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- July 30, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 78% to $629K versus the same quarter last year; diluted EPS -$0.72 versus -$1.14.
- July 30, 2026
- June 18, 2026
- May 21, 2026Other event 8-K
- May 15, 2026Passive stake changed SCHEDULE 13G/A
- May 15, 2026Passive stake (5% or more) SCHEDULE 13G
Insider trades
What the people running Bicycle Therapeutics PLC did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $58.7K worth of shares in the last 90 days and bought none on the open market. 2% of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 5, 2026 | Perry Jennifer ScottChief Operating Officer | Soldpre-planned (10b5-1) | 30 | $107.1 |
| October 5, 2026 | Perry Jennifer ScottChief Operating Officer | Soldpre-planned (10b5-1) | 326 | $1.2K |
| October 5, 2026 | Skynner MichaelCHIEF SCIENTIFIC OFFICER | Sold | 503 | $1.8K |
| October 5, 2026 | Lee KevinCHIEF EXECUTIVE OFFICER, Director | Sold | 1,638 | $5.8K |
| October 5, 2026 | Thompson Travis AlvinChief Financial Officer | Sold | 79 | $282 |
| October 5, 2026 | Hannay Michael Charles FergusonCHIEF PROD & SUPPLY CHAIN OFF | Sold | 242 | $863.9 |
| October 2, 2026 | Skynner MichaelCHIEF SCIENTIFIC OFFICER | Sold | 1,942 | $6.7K |
| October 2, 2026 | Lee KevinCHIEF EXECUTIVE OFFICER, Director | Sold | 6,167 | $21.4K |
Who owns BCYC
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Baker Bros. Advisors LP13D, may seek influence with 3 related filers | 22.9% | December 17, 2024 |
| Forbion Growth Opportunities Fund II Cooperatief U.A.13G, passive with 1 related filers | 7.3% | December 19, 2024 |
| Armistice Capital, LLC13G, passive with 1 related filers | 6.72% | August 14, 2026 |
| Long Focus Capital Management, LLC13G, passive with 1 related filers | 6.6% | May 15, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 104 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Baker Bros. Advisors LP | 10,885,357 | 0 |
| Fcpm III Services B.V. | 3,468,430 | 0 |
| Armistice Capital, LLC | 3,398,000 | 0 |
| Long Focus Capital Management, LLC | 3,310,687 | 0 |
| Renaissance Technologies LLC | 1,533,400 | +554,100 |
| GSK plc | 1,529,561 | 0 |
| Marshall Wace, Llp | 797,940 | +420,605 |
| Qube Research & Technologies Ltd | 775,567 | +466,950 |
| Morgan Stanley | 667,269 | +48,942 |
| Schroder Investment Management Group | 615,833 | 0 |
| Citadel Advisors LLC | 554,225 | +177,140 |
| Millennium Management LLC | 553,967 | +269,981 |
| Peapod Lane Capital LLC | 537,978 | +416,872 |
| Diadema Partners LP | 462,724 | -13,700 |
| Two Sigma Investments, LP | 434,577 | +269,777 |
| Flax Pond Capital, LLC | 376,222 | +200,086 |
| Jane Street Group, LLC | 392,163 | +174,048 |
| Birchview Capital, LP | 313,616 | -149,983 |
| BlackRock, Inc. | 280,386 | +1,394 |
| Moore Capital Management, LP | 275,000 | 0 |
Insiders
16 insiders reported holding 11,594,722 shares in total, about $43.7M at the last price.
| Holder | Shares |
|---|---|
| Baker Bros. Advisors LPDirector, 10% owner | 10,018,67410,018,674 held indirectly |
| Lee KevinCHIEF EXECUTIVE OFFICER, Director | 595,866 |
| Winter Gregory PaulDirector | 196,427 |
| Skynner MichaelCHIEF SCIENTIFIC OFFICER | 154,726 |
| Milnes AlistairCHIEF OPERATING OFFICER | 136,717 |
| Hannay Michael Charles FergusonCHIEF PROD & SUPPLY CHAIN OFF | 92,561 |
| Perry Jennifer ScottChief Operating Officer | 89,602 |
| Young AlethiaChief Financial Officer | 87,081 |
| Thompson Travis AlvinChief Financial Officer | 64,449 |
| Bourque JaniceDirector | 32,500 |
Questions about BCYC
What does Bicycle Therapeutics PLC do?
Bicycle Therapeutics PLC is a company in the Health care sector, listed on NASDAQ as BCYC. Its shares trade on NASDAQ under the ticker BCYC.
What is Bicycle Therapeutics PLC's net worth?
Bicycle Therapeutics PLC has a market value (market cap) of $263.9M at the latest share price, and shareholders' equity of $505.3M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Bicycle Therapeutics PLC profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $141.8M on revenue of $83.5M.
How much revenue does Bicycle Therapeutics PLC make?
Over the twelve months to September 30, 2026 Bicycle Therapeutics PLC reported revenue of $83.5M. That is 194.7% more than a year earlier.
When did Bicycle Therapeutics PLC last report?
Its most recent periodic report is the quarterly report (10-Q) filed on October 29, 2026. It covers the period to September 30, 2026.
When is Bicycle Therapeutics PLC's next earnings report?
Bicycle Therapeutics PLC's next report is expected around March 16, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare BCYC with
Follow BCYC
Get an email when Bicycle Therapeutics PLC files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Bicycle Therapeutics PLC tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.